Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

Phase 1 Completed 20 enrolled F2G Ltd Hammersmith Medicines Research · collab

NaSingle-groupOpen-labelTreatment

Summary

Open label evaluation of potential interaction of F901318 with cytochrome P450 3A4 using midazolam as a probe. Twenty healthy male subjects will participate

Timeline

Start: 2016-01
Primary completion: 2016-06
Completion: 2016-06

Publications

Cornelissen K, Rex JH, Zinzi D, Law D, Upcott Gill R, Jones HM, Maertens J, Chen SC-A, Bruggemann R. Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim. Antimicrob Agents Chemother. 2026 Jun 3;70(6):e0174525. doi: 10.1128/aac.01745-25. Epub 2026 Apr 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Midazolam	Small molecule	2 mg	Oral
Subject	Olorofim	Small molecule	2.5 mg/kg	Intravenous

Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

Summary

Timeline

Publications

Drugs

Indications